{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:42:03Z","timestamp":1786718523250,"version":"build-2736575974"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/ijp.ijp_21_17","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T04:55:42Z","timestamp":1525064142000},"page":"44","source":"Crossref","is-referenced-by-count":12,"title":["Is tapentadol a potential Trojan horse in the postdextropropoxyphene era in India?"],"prefix":"10.4103","volume":"50","author":[{"given":"Aniruddha","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayant","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruva","family":"Ithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PrabhatKumar","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.231474-1","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1517\/14656566.2012.696097","article-title":"Mechanistic and functional differentiation of tapentadol and tramadol","author":"Raffa","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/0253-7613.231474-2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.36076\/ppj.2013\/16\/27","article-title":"Efficacy of tapentadol ER for managing moderate to severe chronic pain","author":"Afilalo","year":"2013","journal-title":"Pain Physician"},{"key":"key-10.4103\/0253-7613.231474-3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/pme.12524","article-title":"Tapentadol abuse potential: A postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment","author":"Butler","year":"2015","journal-title":"Pain Med"},{"key":"key-10.4103\/0253-7613.231474-4","unstructured":"Expert Committee on Drug Dependence. Tapentadol Pre-Review Report. Expert Committee on Drug Dependence Thirty-Fifth Meeting Hammamet, Tunisia; 4-8 June, 2012."},{"key":"key-10.4103\/0253-7613.231474-5","unstructured":"Food and Drugs Administration Government of Goa, India \u2013 Restriction on Use of Formulations of Tramadol, Tapentadol as Well as FDC's Containing Tramadol. Available from: http:\/\/www.dfda.goa.gov.in\/help\/45\/250. [Last accessed on 2016 Aug 28]."}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:36:05Z","timestamp":1786714565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_21_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"alternative-id":["231474"],"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_21_17","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}